SUBSCRIBE
SUBSCRIBE

AbbVie

AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas –immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on X, Facebook, Instagram, YouTube, LinkedIn and Tik Tok.

  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
1 North Waukegan Road
North Chicago, IL 60064
Visit website
Stock Symbol: ABBV
Stock Exchange: NYSE
  • Featured Employer
Together, we break through.

Our principles are at the Heart of our Company. Operating as one AbbVie team, we care deeply for our patients, their families, our employees, and our communities. We strive to always do the right thing, pursuing the highest standards in quality, compliance, safety, and performance. In everything we do, we invest and innovate relentlessly to tackle unmet needs, creating new medicines and healthcare approaches for a healthier world.

How we work with each other and achieve results matters. That’s why we’ve been honored to receive some of the most prestigious ratings and recognitions in the industry, including being named on more than 40 Great Place to Work and Top Employer lists and FORTUNE “100 Best Companies to Work For.”

Click here to learn more about our principles.

NEWS
SKYRIZI is the new option for psoriatic arthritis.
Drug Development
AbbVie’s Rinvoq Shows Promise as Maintenance Drug for Ulcerative Colitis Treatment
Rinvoq shows promising results for Ulcerative Colitis Treatment. The company said more patients treated with Rinvoq in the 52-week study achieved clinical remission compared to placebo.
June 29, 2021
 · 
3 min read
 · 
Alex Keown
Courtesy of Smith Collection/Gado/Getty Images
Drug Development
With Myeloma Drug Proving Merit in Phase I, AbbVie Scoops Up TeneoOne
The decision to exercise the option was based on an interim analysis of the ongoing Phase I trial of TNB-383B.
June 24, 2021
 · 
2 min read
 · 
Mark Terry
Photo courtesy of Capsida Biotherapeutics Inc.
Business
CRISPR and Capsida Partner in Gene Edited Therapies for ALS, Friedreich’s Ataxia
Per the agreement, CRISPR will lead the research and development of the Friedreich’s ataxia program, while Capsida will shepherd the R&D for the ALS effort.
June 14, 2021
 · 
3 min read
 · 
Heather McKenzie
Business
AbbVie Partners With Caraway to Develop Parkinson’s Disease Therapeutics
The collaboration agreement will see the development and commercialization of the target, TMEM175 involved in Parkinson’s disease and other neurodegenerative conditions.
June 9, 2021
 · 
3 min read
 · 
Brandon May
Business
Kojin Therapeutics Debuts to Solve Difficult Diseases Through Cell Behavior
Kojin launched with a $60 million Series A to focus on oncology and cell state biology led by Polaris Partners, Newpath Partners and Cathay Health.
June 9, 2021
 · 
3 min read
 · 
Mark Terry
Policy
Pharma on Trial: Multiple Companies are in Legal Crosshairs
AbbVie has been the target of multiple legal inquiries and challenges of its pricing and patent protections. Now, a U.S. senator is taking a gander at the company’s taxes.
June 3, 2021
 · 
3 min read
 · 
Alex Keown
Courtesy of Abbvie Inc.
Drug Development
Migraines Be Gone: AbbVie’s Atogepant Reduces Headache Frequency and Severity
Migraine headaches can be reduced in frequency and severity by atogepant, an oral therapy developed by AbbVie. So migraines will be gone sooner than we think.
June 3, 2021
 · 
4 min read
 · 
Gail Dutton
Business
Female-Founded and Funded Capsida Taps Swati Tole as Chief Medical Officer
Newly entrenched in a leadership role within one of the most complex therapeutic spaces, Tole discussed the complexities of being both a woman and a woman of color in the biotech industry.
June 1, 2021
 · 
4 min read
 · 
Heather McKenzie
Courtesy of Smith Collection/Gado/Getty Images
Drug Development
AbbVie Hopefuls Skyrizi and Rinvoq Show Promise in Quest to Succeed Humira
AbbVie is aiming Skyrizi and Rinvoq at various indications to augment expected declines in the use of its $20-billion-generating-powerhouse Humira, which will lose patent protection in 2023.
May 25, 2021
 · 
3 min read
 · 
Alex Keown
Load More
JOBS
View All Jobs at AbbVie
IN THE PRESS
Drug Development
AbbVie Presents Positive Investigational Navitoclax Combination Data in Phase 2 REFINE Study Suggesting Anti-Fibrosis Activity for Patients with Myelofibrosis
April 12, 2022
 · 
8 min read
Job Trends
AbbVie to Showcase Breadth of Neuroscience Portfolio and Pipeline at American Academy of Neurology (AAN) 2022 Annual Meeting
March 29, 2022
 · 
28 min read
Biotech Beach
Allergan Aesthetics Brings Data, Innovation & Industry Expertise To The 2022 Aesthetic And Anti-Aging Medicine World Congress (AMWC)
March 29, 2022
 · 
3 min read
Job Trends
AbbVie and Allergan Aesthetics to Present New Research Across Dermatology Portfolio at 2022 AAD Annual Meeting
March 21, 2022
 · 
30 min read
FDA
RINVOQ® (upadacitinib) Receives FDA Approval for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
March 16, 2022
 · 
22 min read
BioMidwest
Now Available Over the Counter, LASTACAFT® Provides Eye Allergy Itch Relief in Minutes that Lasts Through 16 Hours
March 15, 2022
 · 
5 min read
Business
AbbVie and Scripps Research Announce Collaboration to Develop Antiviral Treatments for COVID-19
March 15, 2022
 · 
3 min read
Business
AbbVie and Gedeon Richter Announce Collaboration in Neuropsychiatric Diseases
March 11, 2022
 · 
11 min read
Drug Development
AbbVie Announces Positive Phase 3 Atogepant (QULIPTA™) Data for the Preventive Treatment of Chronic Migraine
March 10, 2022
 · 
15 min read
Policy
Alvotech Resolves U.S. Patent and Trade Secret Disputes with AbbVie, Securing U.S. Rights for Alvotech’s Proposed High-Concentration Biosimilar (AVT02) for Humira®
March 8, 2022
 · 
12 min read
Load More